Skip to product information
1 of 1

Elabscience

SKU:PKSR030476

Recombinant 2019-nCoV Spike Protein (RBD-SD1, mFc Tag)

Recombinant 2019-nCoV Spike Protein (RBD-SD1, mFc Tag)

Regular price $253.00 USD
Regular price Sale price $253.00 USD
Sale Sold out
Shipping calculated at checkout.
Size
Introducing the Recombinant 2019-nCoV Spike Protein (RBD-SD1, MFC TAG), a cutting-edge product designed to meet the demands of the current global health crisis. This meticulously engineered protein offers a highly effective solution for research and diagnostic purposes related to the novel coronavirus (2019-nCoV).

Crafted with utmost precision, the Recombinant 2019-nCoV Spike Protein (RBD-SD1, MFC TAG) showcases an exceptional level of purity and quality. Its recombinant nature ensures a reliable and consistent supply, enabling researchers and scientists to conduct their investigations with utmost confidence.

The inclusion of the receptor-binding domain (RBD) and subdomain 1 (SD1) in this protein variant allows for targeted studies on the interaction between the 2019-nCoV spike protein and its host receptor. This invaluable feature facilitates a deeper understanding of the virus's behavior, aiding in the development of effective therapeutic interventions and diagnostic tools.

Furthermore, the MFC tag incorporated into the Recombinant 2019-nCoV Spike Protein (RBD-SD1, MFC TAG) enables easy detection and purification, streamlining laboratory workflows and enhancing experimental efficiency. This tag, coupled with the protein's exceptional stability, ensures optimal performance and reproducibility in a wide range of applications.

In summary, the Recombinant 2019-nCoV Spike Protein (RBD-SD1, MFC TAG) stands as a testament to scientific innovation and dedication to public health. Its unrivaled purity, reliability, and versatility make it an indispensable tool for researchers, clinicians, and diagnostic laboratories striving to combat the ongoing pandemic. Embrace this exceptional product and empower your endeavors in the fight against 2019-nCoV.
View full details